Teva Gambles Indictment Is Better Than Pleading Guilty To US Price-Fixing Claims
Teva’s market overhang and legal uncertainty intensifies with DOJ charges it conspired to fix generic drug prices. Five other companies have pled guilty and reached deferred prosecution agreements.
You may also be interested in...
Government claims Teva’s payments to two foundations to cover Copaxone copays violated Anti-Kickback statute. Teva is bucking settlement trend in DOJ’s industrywide investigation of sponsor ties to charitable foundations.
Litigation involving Teva has been selected as a “bellwether” case, making it a priority for trial as part of the ongoing US investigation into generic price-fixing.
Complaint names 26 generic dermatologic drug manufacturers and 10 individual executives as defendants, alleging they engaged in a widespread conspiracy to artificially inflate and manipulate prices. State attorneys general say that structural and personnel changes at the companies fostered and facilitated collusion.